Krka has launched Robexera 20 mg/ml injectable solution, giving UK veterinary clinicians the first generic robenacoxib injectable option for perioperative pain and inflammation in cats and dogs.

Krka says Robexera injectable acts within an hour, has a 24-hour duration and that its high COX-2 selectivity reduces wider systemic impact.1

The company says that in cats, the perioperative case is particularly strong, pointing to research which it says showed robenacoxib to have the best proven safety profile in cats of all NSAIDs.1

Krka adds that it is also highly effective in reducing post-operative pain, with evidence of superior efficacy to meloxicam,2 and a proven anaesthetic-sparing effect during feline surgery.3  

Will Ridgway, Head of Animal Health at Krka UK, said: “Practices want product assurance and commercial value. As a bioequivalent to the originator product,4 Robexera injectable delivers both."

https://www.vmd.defra.gov.uk/productinformationdatabase/files/SPC_Documents/SPC_3090863.PDF 

References

  1. Lees, P., et al. (2022). Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib. Journal of Veterinary Pharmacology and Therapeutics, 45, 325–351. https://doi.org/10.1111/jvp.13052.
  2. Kamata, M. et al. (2012) Comparison of injectable robenacoxib versus meloxicam for peri-operative use in cats: results of a randomised clinical trial. The Veterinary Journal vol. 193, Issue 1, July 2012, Pages 114-115. DOI: 10.1016/j.tvjl.2011.11.026
  3. Rosa, L. et al (2024) Effects of Robenacoxib on the minimum alveolar concentration of isoflurane in domestic felines. Arquivo Brasileiro de Medicina Veterinária e Zootecnia 76(6) DOI: 10.1590/1678-4162-13111
  4. Regulatory approved Biowaiver demonstrating bioequivalence to the reference (Registration procedure UK(GB) Vm 01656/5117; PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT; available on https://www.vmd.defra.gov.uk/productinformationd